- Home
- INZY vs FENC Comparison
INZY vs FENC Comparison
Compare INZY & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- FENC
- Stock Information
- Founded
- INZY 2015
- FENC 1996
- Country
- INZY United States
- FENC United States
- Employees
- INZY N/A
- FENC N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INZY Health Care
- FENC Health Care
- Exchange
- INZY Nasdaq
- FENC Nasdaq
- Market Cap
- INZY 188.2M
- FENC 156.9M
- IPO Year
- INZY 2020
- FENC 2001
- Fundamental
- Price
- INZY $1.42
- FENC $6.73
- Analyst Decision
- INZY Strong Buy
- FENC Strong Buy
- Analyst Count
- INZY 8
- FENC 2
- Target Price
- INZY $17.75
- FENC $14.00
- AVG Volume (30 Days)
- INZY 1.0M
- FENC 58.2K
- Earning Date
- INZY 03-11-2025
- FENC 03-20-2025
- Dividend Yield
- INZY N/A
- FENC N/A
- EPS Growth
- INZY N/A
- FENC N/A
- EPS
- INZY N/A
- FENC N/A
- Revenue
- INZY N/A
- FENC $49,348,000.00
- Revenue This Year
- INZY N/A
- FENC $170.43
- Revenue Next Year
- INZY N/A
- FENC $6.70
- P/E Ratio
- INZY N/A
- FENC N/A
- Revenue Growth
- INZY N/A
- FENC 278.09
- 52 Week Low
- INZY $1.24
- FENC $3.96
- 52 Week High
- INZY $7.80
- FENC $11.49
- Technical
- Relative Strength Index (RSI)
- INZY 31.52
- FENC 67.46
- Support Level
- INZY $1.35
- FENC $6.30
- Resistance Level
- INZY $1.45
- FENC $6.76
- Average True Range (ATR)
- INZY 0.12
- FENC 0.28
- MACD
- INZY 0.04
- FENC 0.06
- Stochastic Oscillator
- INZY 43.42
- FENC 93.98
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.